Press releases

All Press releases are available in Swedish.

Cyxone enters into co-operation agreement with University of Queensland

Cyxone AB and the University of Queensland in Australia are launching a co- operation agreement to continue studies into the effects of Cyxone's T20K development substance in combating MS.

Cyxone has signed an agreement with the University of Queensland to study how "therapeutic dosing" with T20K can inhibit the development of fresh MS symptoms in treated animals. The programme will seek to identify the conditions for early treatment with T20K in humans, and is included in the documentation that forms the basis for further studies in humans.

The co-operation agreement covers several studies in 2017, and has a total budget of approximately SEK 1 million.

The research group at the University of Queensland has extensive experience of studies in the MS-mice model, and the work will be followed-up on site by Dr. Christian Gruber, who heads Cyxone's scientific board.

Through the co-operation agreement with the University of Queensland, we feel confident of achieving high quality results with T20K for Cyxone's continued development.

For more information, please contact:
Cyxone AB (publ.)
Kjell G. Stenberg, CEO
Tel: +46 (0) 723 816 168
Email: kjell.g.stenberg@cyxone.com
Adelgatan 21
211 22 Malmö
cyxone.com

This information is information which Cyxone AB (publ) is obliged to publish under the EU Market Abuse Regulation. The information was provided by the auspices of the above contact person, for publication on June 7, 2017.

About Cyxone Cyxone AB (publ.) is a biopharmaceutical company that develops drugs based on cyclotides, a class of natural plant protein. Cyclotide technology has the potential to provide new drugs with beneficial pharmacological effects on diseases that currently lack safe and effective treatments. The company is focusing on the development of T20K, a substance that inhibits key processes in cells that are typically associated with various immune disorders, such as multiple sclerosis and rheumatoid arthritis. Cyxone's Certified Adviser on the Nasdaq First North is Erik Penser Bank.

October 13, 2017
Regulatory

In collaboration with the Medical University of Vienna, Cyxone is set to conduct a study into inflammatory bowel disease involving a cyclotide in established animal models. The study will begin early in 2018.

Read more
October 06, 2017
Regulatory

Cyxone has licensed patent applications at various stages of approval in Europe, North America and Australia. In the US, our patent is approved and in other markets patent applications are well on the way to being approved. In Australia, our patent application was accepted in July, since when the company has submitted a final version and paid the required approval fee. 

Read more
October 05, 2017
Regulatory

Due to the interview conducted with Cyxone's CEO by BioStock/Monocl on Thursday, September 28, the company wishes to clarify references made about the extent to which two Phase 2 trials may be equated with a Phase 3 trial.

Read more
October 05, 2017
Regulatory

The subscription period to purchase warrants in TO 2 ended on September 29, 2017, and during the period, 2,467,119 warrant options were exercised for the equivalent number of shares, corresponding to a subscription ratio of around 98.7%. Cyxone thereby receives some SEK 12.3 million before issue costs.

Read more
August 30, 2017
Regulatory

Summary of interim report

Period (2017-01-01-2017-06-30)

  • Operating revenue KSEK 0 (0)
  • Income after financial items KSEK -4 075 (-1 626)
  • Earnings per share -0,27 (-0,13) SEK
  • Cash and cash equivalents, KSEK 28 114 (24 636) as of 2017-06-30
  • Equity ratio 95,2 (87,9) % as of 2017-06-30

Period (2017-04-01-2017-06-30)

  • Operating revenue KSEK 0 (0)
  • Income after financial items KSEK -2 588 (-1 157)
  • Earnings per share SEK -0,17 (-0,09) 
Read more
June 14, 2017

Cyxone signs acquisition agreement for candidate drug in Phase 2 Cyxone can announce today that the company has signed an agreement pertaining to the exclusive rights to acquire the clinical candidate drug Rabeximod from OxyPharma AB. The transaction has been structured so as to minimise the impact on Cyxone's cash flow by offering the seller 1,916,372 shares, (one million, nine hundred and sixteen thousand, three hundred and seventy two shares amounting to a dilution of 12.5 per cent), as well as royalty rights amounting to ten (10) per cent of future net earnings from Rabeximod. Cyxone will call an extraordinary general meeting to seek shareholder approval for a directed new share issue. This will pave the way for the acquisition and a Phase 2b-study in rheumatoid arthritis.

Read more
June 07, 2017

Cyxone AB and the University of Queensland in Australia are launching a co- operation agreement to continue studies into the effects of Cyxone's T20K development substance in combating MS.

Read more
May 18, 2017

Cyxone can announce today that it has established a long-term strategic co-operation agreement with Sourcia, a clinical contract research organization (CRO) with offices in Belgium, Germany, and the Netherlands.

Read more
May 16, 2017
Regulatory

Period (2017-01-01-2017-03-31)

  • Operating revenue KSEK 0 (0)
  • Income after financial items KSEK -1491 (-307)
  • Earnings per share -0,10 (-0,04) SEK
  • Cash and cash equivalents (2017-03-31) 31 275 (4 114) KSEK
  • Equity ratio 98,2 (97,8) % as of 2017-03-31
Read more
May 15, 2017

Since 2016, Cyxone AB and Swiss pharmaceutical manufacturer Bachem AG have worked closely on the production of syntheses of Cyxone's development substance T20K, and on the production of substances for studies that started last year.

Read more
1
2